Okyo Pharma Ltd. (OK11)
XSTU 
Summary
OK11 Chart
OKYO Pharma poised for breakout as Phase 2 trial nears results: analysts
Shares of OKYO Pharma Ltd (NASDAQ:OKYO) have nearly doubled since the start of the year, fueled by a string of clinical and regulatory milestones that may pave the way for a transformative treatment in the underserved field of ocular pain. In a new note research report, Goldman Small Cap Research raised its price target on the stock to $8, up from $5, citing strong momentum, accelerated clinical progress, and growing interest from patients and clinicians alike in the company's lead drug candidate, urcosimod.
OKYO Pharma CEO to present drug research for debilitating eye pain at Boston summit
OKYO Pharma Ltd (NASDAQ:OKYO) shares could see renewed attention this week as the company's chief executive, Gary Jacob, is set to present findings on its lead drug candidate at a biotech conference in Boston. Jacob will speak at the GPCRs-Targeted Drug Discovery Summit on May 22, where he'll share the latest data on urcosimod, a treatment in development for neuropathic corneal pain—a chronic eye condition that causes severe discomfort and currently has no approved therapies.
OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit
LONDON and NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, and for inflammatory eye diseases, announced that its CEO, Gary S. Jacob, Ph.D., will be giving an oral presentation at the 4th Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA on May 22, 2025. Dr. Jacob's presentation will cover the development of urcosimod, OKYO's lead clinical drug candidate, to treat neuropathic corneal pain (NCP) which is a debilitating condition affecting many tens of thousands worldwide, and is characterized by chronic, severe eye discomfort.
Okyo Pharma Ltd. Dividends
Okyo Pharma Ltd. Earnings
| 2 Oct 2024 Date | | - Cons. EPS | - EPS |
| 30 Sep 2024 Date | | - Cons. EPS | - EPS |
| 27 Sep 2024 Date | | - Cons. EPS | - EPS |
| 25 Sep 2024 Date | | - Cons. EPS | - EPS |
| 23 Sep 2024 Date | | - Cons. EPS | - EPS |
| 2 Oct 2024 Date | | - Cons. EPS | - EPS |
| 30 Sep 2024 Date | | - Cons. EPS | - EPS |
| 27 Sep 2024 Date | | - Cons. EPS | - EPS |
| 25 Sep 2024 Date | | - Cons. EPS | - EPS |
| 23 Sep 2024 Date | | - Cons. EPS | - EPS |
Okyo Pharma Ltd. (OK11) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Okyo Pharma Ltd. ever had a stock split?
Okyo Pharma Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Gary S. Jacob CEO | XSTU Exchange | US6793451088 ISIN |
| GB Country | 3 Employees | - Last Dividend | - Last Split | 17 May 2022 IPO Date |
Overview
OKYO Pharma Limited is a clinical-stage biopharmaceutical company based in the United Kingdom, dedicated to the development of innovative therapeutics for patients afflicted with inflammatory eye diseases and ocular pain. The company, founded in 2007 and headquartered in London, has taken significant strides in the biopharmaceutical field, particularly focusing on conditions that affect eye health. With a strong commitment to addressing unmet medical needs, OKYO Pharma is at the forefront of researching and developing advanced treatments that promise to alleviate suffering and improve the quality of life for patients facing eye-related afflictions.
Products and Services
- OK-101
This lead preclinical product candidate is currently in Phase II clinical trials and represents OKYO Pharma’s pioneering approach to treating dry eye disease. Dry eye disease is a prevalent condition that can significantly impact an individual's quality of life, causing discomfort, and in severe cases, impairing vision. OK-101 is being developed with the aim of providing a novel, effective treatment option for patients who suffer from this condition, potentially improving their symptoms and overall eye health.
- OK-201
Another innovative venture by OKYO Pharma, OK-201 is a preclinical analogue candidate derived from bovine adrenal medulla. This lipidated-peptide is being developed for the treatment of neuropathic chronic pain, a condition that remains challenging to manage with current treatment options. By focusing on novel pathways and mechanisms, OKYO Pharma aims to contribute an important solution to the field of pain management, particularly for patients whose quality of life is severely affected by chronic pain conditions.
Contact Information
